No Data
No Data
Express News | Celularity Presents Data On T-Cell Therapy Platform At ASCO Annual Meeting; PT-CD16VS Shows Potent Activity And Potential For Combination With Monoclonal Antibodies To Target Multiple Cancers
Express News | Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Express News | Celularity Granted European Patent EP3957315 For Treatment Of Diabetic Peripheral Neuropathy Using Placental Cells
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
Celularity Inc. to Host Investor and Analyst Research & Development Day
FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
Express News | Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
No Data